halofuginone has been researched along with Dermatoses in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Cheng, H; Li, Z; Pan, B; Song, G; Tian, J; Xu, K; Zeng, L | 1 |
| Bona, C; Kodera, T; McGaha, T; Phelps, R; Pines, M; Spiera, H | 1 |
| Bona, C; McGaha, TL; Phelps, RG; Spiera, H | 1 |
3 other study(ies) available for halofuginone and Dermatoses
| Article | Year |
|---|---|
Halofugine prevents cutaneous graft versus host disease by suppression of Th17 differentiation.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow Transplantation; Cell Differentiation; Chronic Disease; Cytokines; Female; Graft vs Host Disease; Male; Mice; Mice, Inbred BALB C; Piperidines; Quinazolinones; Skin Diseases; Th17 Cells; Time Factors; Transplantation, Homologous | 2012 |
Effect of halofuginone on the development of tight skin (TSK) syndrome.
Topics: Animals; Animals, Newborn; Collagen; Disease Models, Animal; Fibrosis; Humans; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Scleroderma, Systemic; Skin Diseases | 2002 |
Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
Topics: Animals; Cells, Cultured; Collagen; Collagen Type I; DNA-Binding Proteins; Fibroblasts; Gene Expression; Hyperplasia; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Mutant Strains; Piperidines; Quinazolines; Quinazolinones; Receptors, Transforming Growth Factor beta; Sclerosis; Signal Transduction; Skin; Skin Diseases; Smad3 Protein; Trans-Activators; Transforming Growth Factor beta | 2002 |